

PATENT CLAIMS

1. Active substance combination consisting of deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamlamine or one of its pharmaceutically acceptable derivatives for the production of a medicament for treating alcohol abuse and/or alcohol dependence.
2. Active substance combination according to claim 1, characterized in that the pharmaceutically acceptable derivative of deoxypeganine is selected from the group consisting of deoxypeganine hydrochloride, 7-bromodeoxypeganine, 7-bromo-6-hydroxy-5-methoxydeoxypeganine, 7-chloro-6-hydroxy-5-methoxydeoxypeganine, 7-fluoro-6-hydroxy-5-methoxydeoxypeganine and 7-iodo-6-hydroxy-5-methoxydeoxypeganine.
3. Active substance combination according to claim 1 or 2, characterized in that the pharmaceutically acceptable derivative of mecamlamine is selected from the group consisting of the salts of mecamlamine with halogen acids or simple organic acids such as tartaric acid, succinic acid, maleic acid and the like.
4. Active substance combination according to any one of the preceding claims, characterized in that mecamlamine is present in the form of the racemic mixture of its two stereoisomers or in the form of one of its two stereoisomers.
5. Active substance combination according to any one of the preceding claims, characterized in that the medicament is in the form of a combined administration form for deoxypeganine or one of its pharmaceutically acceptable de-

rivatives and mecamlamine or one of its pharmaceutically acceptable derivatives.

6. Active substance combination according to any one of claims 1 to 4, characterized in that the medicament is in the form of separate administration forms for deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamlamine or one of its pharmaceutically acceptable derivatives.

7. Active substance combination according to any one of the preceding claims, characterized in that the medicament is in the form of an administration form to be administered orally or parenterally, preferably transdermally.

8. Active substance combination according to claim 7, characterized in that it is in the form of a medicament having depot effect.

9. Active substance combination according to any one of the preceding claims, characterized in that the daily dose of deoxypeganine or one of its pharmaceutically acceptable salts in the case of an administration form to be administered orally is 50 to 750 mg, preferably 100 to 400 mg.

10. Active substance combination according to any one of claims 1 to 8, characterized in that the daily dose of deoxypeganine or one of its pharmaceutically acceptable salts in the case of an administration form to be administered transdermally is 50 to 250 mg.

11. Active substance combination according to any one of the preceding claims, characterized in that the daily dose of mecamlamine in the case of an administration form to be administered orally is 2.5 to 20 mg, preferably 2.5 to 7.5 mg.

12. Active substance combinations according to any one of claims 1 to 10, characterized in that the daily dose of mecamlamine in the case of an administration form with delayed release is 0.5 to 10 mg.

13. Use of an active substance combination according to any one of the preceding claims for treating alcohol abuse and/or alcohol dependence.

14. Process for treating alcohol abuse and/or alcohol dependence, characterized by the administration of an active substance combination according to any one of claims 1 to 12.

15. Process according to claim 14, characterized in that the administration of the active substance combination is preceded by a pre-treatment with mecamlamine.